Project Grant R01CA299219
Award Date 8/11/26
Completion Date 7/31/31
Dollars Obligated $645K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $155,605 on September 12, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research identifying metabolomic profiles associated with oral contraception use and their relationship to ovarian and breast cancer risk. The project, led by Dr. Mongiovi, will comprehensively quantify changes in circulating metabolites and metabolic pathways linked to oral contraceptive use using machine learning and...
- The National Cancer Institute awarded Brigham & Women's Hospital $772,208 on April 10, 2026, under Cancer Treatment Research (CFDA 93.395) to conduct macrophage-directed strategies for BRCA-associated breast cancer treatment, with performance through March 31, 2031. The recipient is characterizing tumor microenvironment responses to combined PARP inhibition (olaparib) and anti-CSF-1R antibody (axatilimab) therapy in patients enrolled in the AXALAP clinical trial. Work includes analysis of...
- The National Cancer Institute awarded Brigham & Women's Hospital $273,049 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research integrating molecular programs into clinical frameworks to inform optimal thyroid cancer care. The award funds research defining the influence of tumor-specific epithelial-to-mesenchymal transition (EMT) signaling and immune programs on differentiated thyroid carcinoma (DTC) progression and their clinical prognostic...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $756,755 on August 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a structured peer support intervention for patients undergoing hematopoietic stem cell transplantation. The award is classified as a Project Grant with a period of performance through July 31, 2031, and place of performance in Boston, Massachusetts. The intervention, called STEPP (Structured Peer Support Intervention),...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $529,801 on July 9, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate mechanisms by which opioid hormone signaling suppresses CD8+ tumor-infiltrating lymphocyte function and impairs immune checkpoint blockade efficacy in cancer. The research uses single-cell RNA sequencing and functional studies to characterize how tumor-derived opioids—specifically proenkephalin-derived peptides acting through...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $524,110 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393, Assistance Listing Project Grant R01CA314254). The award funds research on one-ended break repair mechanisms in mammalian cells, specifically investigating how cells repair DNA damage at broken replication forks and double-strand...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $409,463 on June 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate eukaryotic translation initiation factor 4A (EIF4A) inhibition as a therapeutic approach for acute myeloid leukemia. The research validates zotatifin, a clinical-grade EIF4A inhibitor, as a small molecule to target AML cells. The central hypothesis is that zotatifin selectively targets AML cells over healthy cells and...
- Brigham & Women's Hospital Inc. was awarded a $1,523,784 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program to investigate cytoplasmic DNA-sensing pathways in BRCA1-deficient breast cancer development. The three-year award beginning July 1, 2022 will support research into medical solutions for breast cancer at the cellular level through studying the role of cytoplasmic DNA sensors in breast cancer tumor growth associated with...
- The National Cancer Institute awarded Beth Israel Deaconess Medical Center $444,569 on September 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate cuproptosis—a copper-dependent form of regulated cell death—as a therapeutic pathway against chemoresistant high-grade serous ovarian cancer (HGSOC). The research addresses HGSOC's clinical challenge: most patients relapse after platinum-based chemotherapy, and recurrent disease develops resistance through adaptive,...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $199,694 in project grant funding on August 18, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and test PROSPER, a resilience-promoting mobile health intervention designed to prevent chronic postsurgical pain in patients undergoing gynecologic oncology surgery. The award funds development of a perioperative psychological intervention adapted from Pain Coping and Resilience Therapy (PCRT),...